Adage Capital Partners Amends Soleno Therapeutics Stake

TL;DR

**Adage Capital Partners updated their Soleno Therapeutics stake, watch for potential market reaction.**

AI Summary

Adage Capital Partners, L.P. filed an amended Schedule 13G/A on February 7, 2024, indicating a change in their ownership of Soleno Therapeutics Inc. common stock as of December 31, 2023. While the filing doesn't specify the exact change in share count or percentage, it signals that Adage Capital Partners, a significant institutional investor, has updated its passive stake. This matters to investors because changes in large institutional holdings can influence stock perception and liquidity, potentially signaling a shift in confidence from a major player.

Why It Matters

This filing shows an update to a major institutional investor's stake in Soleno Therapeutics, which can impact investor sentiment and the stock's trading dynamics.

Risk Assessment

Risk Level: low — This is a routine amendment by a passive investor and does not inherently signal a high-risk event for the company.

Analyst Insight

Investors should monitor future 13G/A filings from Adage Capital Partners for Soleno Therapeutics to track any significant changes in their ownership percentage, which could signal a shift in their investment thesis.

Key Numbers

• $0.001 — par value per share (the par value of Soleno Therapeutics Inc. Common Stock)

Key Players & Entities

• Adage Capital Partners, L.P. (company) — the reporting person and institutional investor
• SOLENO THERAPEUTICS INC (company) — the subject company whose shares are being reported
• December 31, 2023 (date) — the date of the event requiring the filing
• February 7, 2024 (date) — the filing date of the SC 13G/A
• 834203309 (number) — the CUSIP number for Soleno Therapeutics Inc. Common Stock

Forward-Looking Statements

• Adage Capital Partners will maintain a significant, passive stake in Soleno Therapeutics Inc. for the foreseeable future. (Adage Capital Partners, L.P.) — medium confidence, target: December 31, 2024

FAQ

Key Financial Figures

• $0.001 — me of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securitie

Filing Documents

• p24-0474sc13ga.htm (SC 13G/A) — 93KB
• 0000902664-24-001191.txt ( ) — 95KB

(a)

Item 1(a). NAME OF ISSUER: The name of the issuer is Soleno Therapeutics, Inc. (the “ Company ”).

(b)

Item 1(b). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES: The Company’s principal executive offices are located at 203 Redwood Shores Pkwy, Suite 500, Redwood City, CA 94065.

(a)

Item 2(a). NAME OF PERSON FILING: This statement is filed by: (i) Adage Capital Partners, L.P., a Delaware limited partnership (“ ACP ”) with respect to the Common Stock directly owned by it; (ii) Adage Capital Partners GP, L.L.C., a limited liability company organized under the laws of the State of Delaware (“ ACPGP ”), as general partner of ACP with respect to the Common Stock directly owned by ACP; (iii) Adage Capital Management, L.P., a Delaware limited partnership (“ ACM ”), as the investment manager of ACP, with respect to the Common Stock directly owned by ACP; (iv) Robert Atchinson (“ Mr. Atchinson ”), as (1) managing member of Adage Capital Advisors, L.L.C., a limited liability company organized under the laws of the State of Delaware (“ ACA ”), managing member of ACPGP and (2) managing member of Adage Capital Partners LLC, a Delaware limited liability company (“ ACPLLC ”), general partner of ACM, with respect to the Common Stock directly owned by ACP; and (v) Phillip Gross (“ Mr. Gross ”), as (1) managing member of ACA, managing member of ACPGP and (2) managing member of ACPLLC, general partner of ACM, with respect to the Common Stock directly owned by ACP. The foregoing persons are hereinafter sometimes collectively referred to as the “ Reporting Persons .” Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party. The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein.

(b)

Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE: The address of the business office of each of the Reporting Persons is 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116.

(c)

Item 2(c). CITIZENSHIP: ACP is a limited partnership organized under the laws of the State of Delaware. ACPGP and ACA are limited liability companies organized under the laws of the State of Delaware. Messrs. Gross and Atchinson are citizens of the United States. CUSIP No. 834203309 13G/A Page 8 of 10 Pages

(d)

Item 2(d). TITLE OF CLASS OF SECURITIES Common Stock, par value $0.001 per share (the “ Common Stock ”).

(e)

Item 2(e). CUSIP NUMBER 834203309 Item 3. IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A: (a) Broker or dealer registered under Section 15 of the Act; (b) Bank as defined in Section 3(a)(6) of the Act; (c) Insurance company as defined in Section 3(a)(19) of the Act; (d) Investment company registered under Section 8 of the Investment Company Act of 1940; (e) An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); (f) An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); (g) A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act; (i) A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act; (j) A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J); (k) Group, in accordance with Rule 13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: Not applicable . Item 4. The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. The percentage set forth in this Schedule 13G/A is calculated based upon 30,499,352 shares of Common Stock outstanding as of November 3, 2023, as reported in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023 filed with the Securities and Exchange Commission on November 8, 2023. Item 5. Not applicable. CUSIP No. 834203309 13G/A Page 9 of 10 Pages Item 6. Not applicable. Item

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct. DATE: February 7, 2024 ADAGE CAPITAL PARTNERS, L.P. By: Adage Capital Partners GP, L.L.C., its general partner By: Adage Capital Advisors, L.L.C., its managing member /s/ Robert Atchinson Name: Robert Atchinson Title: Managing Member ADAGE CAPITAL PARTNERS GP, L.L.C. By: Adage Capital Advisors, L.L.C., its managing member /s/ Robert Atchinson Name: Robert Atchinson Title: Managing Member ADAGE CAPITAL MANAGEMENT, L.P. By: Adage Capital Partners LLC, its general partner /s/ Robert Atchinson Name: Robert Atchinson Title: Managing Member /s/ Robert Atchinson ROBERT ATCHINSON, individually /s/ Phillip Gross PHILLIP GROSS, individually

View Full Filing

View this SC 13G/A filing on SEC EDGAR